Rigel Pharmaceuticals (RIGL) Non-Current Deffered Revenue (2010 - 2020)

Rigel Pharmaceuticals' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $146000.0 for Q3 2020.

• In Q3 2020, Non-Current Deffered Revenue fell 99.42% year-over-year to $146000.0; the TTM figure through Sep 2020 stood at $146000.0 (down 99.42% YoY), while the FY2019 annual figure was $1.4 million, changed 0.28% from the prior year.
• Non-Current Deffered Revenue for Q3 2020 stood at $146000.0, down from $1.6 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $26.4 million in Q2 2019, with the low at $90000.0 in Q4 2017.
• The 5-year median for Non-Current Deffered Revenue is $1.4 million (2018), against an average of $6.3 million.
• The sharpest annual moves came in 2019 and 2020: Non-Current Deffered Revenue surged 14720.79% in 2019, then sank 99.42% in 2020.
• Rigel Pharmaceuticals' Non-Current Deffered Revenue stood at $279000.0 in 2016, then tumbled by 67.74% to $90000.0 in 2017, then jumped by 1464.44% to $1.4 million in 2018, then slipped by 0.28% to $1.4 million in 2019, then tumbled by 89.6% to $146000.0 in 2020.
• Business Quant data shows RIGL's Non-Current Deffered Revenue at $146000.0 in Q3 2020, $1.6 million in Q1 2020, and $1.4 million in Q4 2019.